2011 ACCF/AHA Focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines - Developed in Collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology

Journal of Vascular Surgery

Volumn 54, Issue 5, 2011, Pages

  Rooke, Thom W ^a   Hirsch, Alan T ^a   Misra, Sanjay ^a   Sidawy, Anton N ^a   Beckman, Joshua A ^a   Findeiss, Laura K ^a   Golzarian, Jafar ^a   Gornik, Heather L ^a   Halperin, Jonathan L ^a   Jaff, Michael R ^a   Moneta, Gregory L ^a   Olin, Jeffrey W ^a   Stanley, James C ^a   White, Christopher J ^a   White, John V ^a   Zierler, R Eugene ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO; VARENICLINE; WARFARIN;

ABDOMINAL AORTA ANEURYSM; AGITATION; AMPUTATION; ANGIOPLASTY; ANKLE BRACHIAL INDEX; BEHAVIOR CHANGE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CLINICAL EXAMINATION; COST EFFECTIVENESS ANALYSIS; DEATH; DEPRESSION; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; ENDOVASCULAR SURGERY; FOLLOW UP; HEART DEATH; HEART INFARCTION; HOSTILITY; HUMAN; LIFE EXPECTANCY; LIMB ISCHEMIA; LIMB SALVAGE; MEDICAL SOCIETY; MONOTHERAPY; NICOTINE REPLACEMENT THERAPY; OPEN SURGERY; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT COUNSELING; PEER REVIEW; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SALVAGE THERAPY; SEGMENTAL PRESSURE EXAMINATION; SIDE EFFECT; SMOKING CESSATION; STROKE; SUICIDAL IDEATION; SURGERY; SURGICAL RISK; TOE BRACHIAL INDEX; TREATMENT INDICATION;

AMERICAN HEART ASSOCIATION; CARDIOVASCULAR AGENTS; ENDOVASCULAR PROCEDURES; HUMANS; PATIENT SELECTION; PERIPHERAL ARTERIAL DISEASE; RADIOGRAPHY, INTERVENTIONAL; RISK REDUCTION BEHAVIOR; SMOKING CESSATION; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES; VASCULAR SURGICAL PROCEDURES;

EID: 80054911880     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2011.09.001     Document Type: Review

References (66)

1. ACCF/AHA Task Force on Practice Guidelines. Methodologies and Policies from the ACCF/AHA Task Force on Practice Guideline. Available at http://assets.cardiosource.com/Methodology-Manual- for-ACC-AHA-Writing- Committees.pdf. Accessed July 1, 2011.
2. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation. 2006;113:1474-547.
3. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75.
4. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/ Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation. 2006;113:e463-654.
5. Wheatley K, Ives N, Gray R, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361:1953-62.
6. Cooper CJ, Murphy TP, Matsumoto A, et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006;152:59-66. (Pubitemid 43974724)
7. Alhadad A, Mattiasson I, Ivancev K, et al. Revascularisation of renal artery stenosis caused by fibromuscular dysplasia: effects on blood pressure during 7-year follow-up are influenced by duration of hypertension and branch artery stenosis. J Hum Hypertens. 2005;19:761-7. (Pubitemid 41486138)
8. Modrall JG, Rosero EB, Smith ST, et al. Operative mortality for renal artery bypass in the United States: results from the National Inpatient Sample. J Vasc Surg. 2008;48:317-22.
9. Criqui MH, Denenberg JO, Bird CE, et al. The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing. Vasc Med. 1996;1:65-71. (Pubitemid 26153813)
10. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-24. (Pubitemid 33015522)
11. Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053-61.
12. Fowkes FG. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol. 1988;17:248-54.
13. Feigelson HS, Criqui MH, Fronek A, et al. Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of noninvasive tests in a defined population. Am J Epidemiol. 1994;140:526- 34.
14. Nassoura ZE, Ivatury RR, Simon RJ, et al. A reassessment of Doppler pressure indices in the detection of arterial lesions in proximity penetrating injuries of extremities: a prospective study. Am J Emerg Med. 1996;14:151-6. (Pubitemid 26090198)
15. Carter SA. Clinical measurement of systolic pressures in limbs with arterial occlusive disease. JAMA. 1969;207:1869-74.
16. Carter SA, Tate RB. Value of toe pulse waves in addition to systolic pressures in the assessment of the severity of peripheral arterial disease and critical limb ischemia. J Vasc Surg. 1996;24:258-65. (Pubitemid 26327772)
17. Carter SA, Tate RB. The value of toe pulse waves in determination of risks for limb amputation and death in patients with peripheral arterial disease and skin ulcers or gangrene. J Vasc Surg. 2001;33:708-14. (Pubitemid 33586621)
18. Brooks B, Dean R, Patel S, et al. TBI or not TBI: that is the question: is it better to measure toe pressure than ankle pressure in diabetic patients? Diabet Med. 2001;18:528-32. (Pubitemid 32823074)
19. Ramsey DE, Manke DA, Sumner DS. Toe blood pressure: a valuable adjunct to ankle pressure measurement for assessing peripheral arterial disease. J Cardiovasc Surg (Torino). 1983;24:43-8. (Pubitemid 13132338)
20. Belcaro G, Nicolaides AN, Bull ML, et al. The value of segmental pressure measurement in the assessment of peripheral vascular disease. Int Angiol. 1986;5:7-12. (Pubitemid 16093632)
21. Gundersen J. Segmental measurements of systolic blood pressure in the extremities including the thumb and the great toe. Acta Chir Scand Suppl. 1972;426:1-90.
22. Johnston KW, Hosang MY, Andrews DF. Reproducibility of noninvasive vascular laboratory measurements of the peripheral circulation. J Vasc Surg. 1987;6:147-51. (Pubitemid 17128038)
23. Kupinski A. Segmental pressure measurement and plethysmography. J Vasc Technol. 2002;1:32-8. (Pubitemid 34408353)
24. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197-208. (Pubitemid 351969304)
25. Nides MA, Rakos RF, Gonzales D, et al. Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study. J Consult Clin Psychol. 1995;63:60-9.
26. Mohiuddin SM, Mooss AN, Hunter CB, et al. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest. 2007;131:446-52. (Pubitemid 46280405)
27. Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev. 2000;131:CD001009.
28. Rothemich SF, Woolf SH, Johnson RE, et al. Effect on cessation counseling of documenting smoking status as a routine vital sign: an ACORN study. Ann Fam Med. 2008;6:60-8.
29. Hennrikus D, Joseph A, Lando H, et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. JACC. 2010;25:2105-12.
30. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
31. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.
32. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166:1561-8. (Pubitemid 44232363)
33. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-91. (Pubitemid 29110752)
34. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust. 1983;1:217-9. (Pubitemid 13093285)
35. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221:253-60. (Pubitemid 17069424)
36. Lassila R, Lepantalo M. Cigarette smoking and the outcome after lower limb arterial surgery. Acta Chir Scand. 1988;154:635-40. (Pubitemid 19069863)
37. Quick CR, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg. 1982;69 Suppl:S24-6. (Pubitemid 12096147)
38. Gardner AW. The effect of cigarette smoking on exercise capacity in patients with intermittent claudication. Vasc Med. 1996;1:181-6. (Pubitemid 26402979)
39. Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med. 1995;155:1933-41.
40. West R, Baker CL, Cappelleri JC, et al. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl). 2008;197:371-7.
41. Knight C, Howard P, Baker CL, et al. The cost-effectiveness of an extended course (12-12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value Health. 2010;13: 209-14.
42. Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med. 2000;343:864-9.
43. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-39.
44. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published correction appears in BMJ. 2002;324:141]. BMJ. 2002;324:71-86.
45. Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007;261:276-84.
46. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
47. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841-8.
48. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-17.
49. Cacoub PP, Bhatt DL, Steg PG, et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30:192-201.
50. Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217-27. (Pubitemid 47080386)
51. Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a metaanalysis of randomized trials. JAMA. 2009;301:1909-19.
52. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-8. (Pubitemid 46694290)
53. Bernstein EF, Rhodes GA, Stuart SH, et al. Toe pulse reappearance time in prediction of aortofemoral bypass success. Ann Surg. 1981;193:201-5. (Pubitemid 11153104)
54. Bradbury AW, Adam DJ, Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg. 2010;51:5S-17S.
55. Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925-34. (Pubitemid 41713982)
56. Greenhalgh RM, Brown LC, Powell JT, et al. Endovascular versus open repair of abdominal aortic aneurysm. N Engl J Med. 2010;362:1863-71.
57. Blankensteijn JD, de Jong SE, Prinssen M, et al. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med. 2005;352:2398-405. (Pubitemid 40958436)
58. De Bruin JL, Baas AF, Buth J, et al. Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. N Engl J Med. 2010;362:1881-9.
59. Greenhalgh RM, Brown LC, Powell JT, et al. Endovascular repair of aortic aneurysm in patients physically ineligible for open repair. N Engl J Med. 2010;362:1872-80.
60. Lederle FA, Freischlag JA, Kyriakides TC, et al. Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. JAMA. 2009;302:1535-42.
61. Brown LC, Epstein D, Manca A, et al. The UK Endovascular Aneurysm Repair (EVAR) trials: design, methodology and progress. Eur J Vasc Endovasc Surg. 2004;27:372-81. (Pubitemid 38386922)
62. Schanzer A, Hevelone N, Owens CD, et al. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg. 2008;47: 774-81.
63. Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43: 742-51.
64. Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: crosssectional study. Atherosclerosis. 2004;172:95-105. (Pubitemid 38058606)
65. Hennrikus D, Joseph AM, Lando HA, et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol. 2010;56:2105-12.
66. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004;148:263-8. (Pubitemid 39092790)